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Abstract
Background:  The  aim  of  this  study  was  to  investigate  the  effects  of  intracerebroventricularly
administered  rocuronium  bromide  on  the  central  nervous  system,  determine  the  seizure  thresh-
old dose  of  rocuronium  bromide  in  rats,  and  investigate  the  effects  of  rocuronium  on  the  central
nervous system  at  1/5,  1/10,  and  1/100  dilutions  of  the  determined  seizure  threshold  dose.
Methods:  A  permanent  cannula  was  placed  in  the  lateral  cerebral  ventricle  of  the  animals.  The
study was  designed  in  two  phases.  In  the  ﬁrst  phase,  the  seizure  threshold  dose  of  rocuronium
bromide  was  determined.  In  the  second  phase,  Group  R  1/5  (n  =  6),  Group  1/10  (n  =  6),  and  Group
1/100 (n  =  6)  were  formed  using  doses  of  1/5,  1/10,  and  1/100,  respectively,  of  the  obtained
rocuronium  bromide  seizure  threshold  dose.
Results:  The  rocuronium  bromide  seizure  threshold  value  was  found  to  be  0.056  ±  0.009  moL.
The seizure  threshold,  as  a  function  of  the  body  weight  of  rats,  was  calculated  as
0.286 moL/kg−1.  A  dose  of  1/5  of  the  seizure  threshold  dose  primarily  caused  splayed  limbs,
posturing, and  tremors  of  the  entire  body,  whereas  the  dose  of  1/10  of  the  seizure  thresh-
old dose  caused  agitation  and  shivering.  A  dose  of  1/100  of  the  seizure  threshold  dose  was
associated  with  decreased  locomotor  activity.
Conclusions:  This  study  showed  that  rocuronium  bromide  has  dose-related  deleterious  effects
on the  central  nervous  system  and  can  produce  dose-dependent  excitatory  effects  and  seizures.
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Efeitos  da  administrac¸ão intracerebroventricular  de  rocurônio  sobre  o  sistema
nervoso  central  de  ratos  e  determinac¸ão da  dose  indutora  de  crise  epiléptica
Resumo
Justiﬁcativa:  O  objetivo  deste  estudo  foi  investigar  os  efeitos  do  brometo  de  rocurônio  admin-
istrado intracerebroventricularmente  sobre  o  sistema  nervoso  central,  determinar  a  dose  do
limiar convulsivo  de  rocurônio  em  ratos  e  investigar  os  efeitos  de  rocurônio  no  sistema  nervoso
central em  diluic¸ões  de  1/5,  1/10  e  1/100  da  dose  do  limiar  convulsivo  determinada.
Métodos:  Uma  cânula  permanente  foi  colocada  no  ventrículo  lateral  do  cérebro  dos  animais.  O
estudo foi  projetado  em  duas  fases.  Na  primeira  fase,  a  dose  do  limiar  convulsivo  do  brometo  de
rocurônio foi  determinada.  Na  segunda  fase,  o  Grupo  R  1/5  (n  =  6),  Grupo  1/10  (n  =  6)  e  Grupo
1/100 (n  =  6)  foram  formados  usando  doses  de  1/5,  1/10  e  1/100,  respectivamente,  da  dose  do
limiar convulsivo  de  brometo  de  rocurônio  obtida.
Resultados:  Descobrimos  que  o  valor  do  limiar  convulsivo  de  brometo  de  rocurônio  é
0,056 ±  0,009  moL.  O  limiar  convulsivo,  como  uma  func¸ão  do  peso  corporal  dos  ratos,  foi
calculado como  0,286  moL/kg−1.  Uma  dose  de  1/5  da  dose  do  limiar  convulsivo  causou  princi-
palmente  abertura  postural  dos  membros  e  tremores  em  todo  o  corpo,  enquanto  uma  dose  de
1/10 da  dose  do  limiar  convulsivo  causou  agitac¸ão  e  tremores.  Uma  dose  de  1/100  da  dose  do
limiar convulsivo  foi  associada  à  diminuic¸ão  da  atividade  locomotora.
Conclusões:  Este  estudo  mostrou  que  o  brometo  de  rocurônio  possui  efeitos  deletérios  rela-
cionados  com  a  dose  sobre  o  sistema  nervoso  central  e  pode  produzir  efeitos  excitatórios
dependentes  da  dose  e  convulsões.
Publicado  por  Elsevier  Editora  Ltda.  em  nome  de  Sociedade  Brasileira  de  Anestesiologia.  Este
e´ um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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n  cases  in  which  neuromuscular  blocking  drugs  have
een  administered  accidentally  into  the  cerebrospinal  ﬂuid
CSF),1 myotonia,  autonomic  changes,  and  convulsions  have
ccurred.2 Prolonged  administration  of  rocuronium  in  crit-
cal  care  patients  has  resulted  in  the  drug  entering  the
SF.3 Also  in  patients  with  impaired  function  of  the  blood
rain  barrier  these  molecules  may  reach  the  CSF.  Tassonyi
t  al.4 has  reported  that  some  neuromusculer  agents  like
tracurium  and  its  metabolite  laudanosine  present  in  the
SF,  vecuronium  could  not  be  detected  in  CSF  in  the  sub-
rachnoid  hemorrhage.  And  also  atracurium  persisted  in  the
SF  for  several  hours  after  the  end  of  the  infusion.  Although
t  is  a  non-depolarizing,  ionized  medication  with  relatively
ow  lipophilicity,  it  is  known  that  rocuronium  can  permeate
he  CSF  after  intravenous  injection.5 Accidental  administra-
ion  of  rocuronium  into  the  central  nervous  system  (CNS)
uring  regional  anesthesia  has  been  reported.6 There  are
imited  data  regarding  the  effects  of  these  drugs  on  the  CNS.
The  aim  of  this  study  was  to  investigate  the  effects
f  intracerebroventricularly  administered  rocuronium  bro-
ide  on  the  CNS,  determine  the  seizure  threshold  dose  of
ocuronium  bromide  in  rats,  and  investigate  the  effects  of
ocuronium  on  the  CNS  at  1/5,  1/10,  and  1/100  dilutions  of
he  seizure  threshold  dose.ethods
he  study  protocol  was  approved  by  the  Animal  Research
ommittee  of  Dokuz  Eylul  University.  Thirty-six  female
t
s
o
Tistar  albino  rats  that  were  bred  in  the  Experimental
esearch  Laboratory  of  Dokuz  Eylul  University  were  used  in
he  study.  The  rats  weighed  180--260  g  and  were  87%  homo-
eneous,  were  aged  18--24  months,  and  exhibited  normal
ctivity.  The  animals  were  kept  under  standard  laboratory
onditions  for  one  week  before  the  experiments  began  (12  h
ight:  12  h  light,  20--22 ◦C  room  temperature)  to  adapt  to
he  environment.  They  had  free  access  to  water  and  pellet
ood,  and  the  study  was  conducted  in  a  noise-attenuated
nvironment  and  at  the  same  time  each  day.
urgery
nesthesia  was  induced  by  intraperitoneal  injection  of
0  mg/kg−1 sodium  thiopental  (Pental® Sodyum  I.E.  Ulugay
lac¸  San.  TAS,  Istanbul,  Turkey)  while  maintaining  sponta-
eous  respiration  and  the  blink  reﬂex.  The  rats  were  placed
n  the  prone  position,  and  a  4  cm  ×  2  cm  area  between  the
ars  and  extending  toward  the  nasus  was  shaved.  The  area
as  cleaned  with  povidon  iodine,  1  mL  of  sterile  1%  lido-
aine  (Aritmal® 2%  amp,  Biosel  Ilac¸  Sanayi  ve  Ticaret  A.S,
stanbul,  Turkey)  was  inﬁltrated  under  the  scalp,  and  a  mid-
ine  surgical  incision  was  made.  The  head  of  the  animal  was
laced  in  a  stereotaxic  frame  where  the  head  was  secured  in
 ﬂexed-forward  position.  The  skin  was  laterally  reﬂected,
nd  the  exposed  cranium  was  gently  blunt-dissected  with
he  bregma  exposed.  A  2  mm  hole  for  the  intracerebroven-
ricular  rocuronium  bromide  injection  was  bored  at  the
tereotaxic  coordinates,  determined  according  to  the  atlas
f  Paxinos  and  Watson,7 to  access  the  lateral  ventricle.
he  cannula  used  for  the  intracerebroventricular  procedures
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(C311/G,  20G,  Plastics  One  Inc.,  VA,  USA)  and  a  suitable
stylet  (C311/DC,  Plastics  One  Inc.,  VA,  USA)  to  prevent  tis-
sue  and/or  foreign  bodies  from  moving  into  the  cannula  were
placed.  The  placement  of  the  cannula  in  the  lateral  ven-
tricle  was  conﬁrmed  by  CSF  drainage  through  the  cannula.
The  edges  of  the  incision  were  approximated,  sutured  with
2/0  silk  thread,  and  cleaned  with  10%  povidon  iodine.  These
procedures  were  conducted  under  sterile  conditions.  Forty-
eight  hours  were  allowed  for  the  usual  activity  of  the  rats  to
be  restored  after  this  intervention.  The  purpose  of  placing
a  permanent  cannula  was  to  enable  ICV  drug  administration
while  the  rats  were  awake  and  mobile.
Preparation  of  the  drug
A  stock  solution  with  0.016  moL  rocuronium  bromide
(Esmeron®,  Organon  Corp,  Oss,  Holland)  in  10  L was  used
to  determine  the  seizure  threshold  dose  of  rocuronium  bro-
mide.
Following  the  determination  of  the  seizure  threshold
dose  of  rocuronium,  the  1/5,  1/10,  and  1/100  dilutions  in
10  L  Ringer’s  lactate  solution  (Ringer  lactate,  Biosel  Ilac
San.  TAS,  Istanbul,  Turkey)  were  prepared.
The  pH  values  of  the  rocuronium  bromide,  Ringer’s  lac-
tate,  and  rocuronium  bromide-Ringer’s  lactate  solutions  at
23 ◦C  were  measured  with  a  pH  meter  (InoLab® 720,  WTW
Wissenschaftlich-Technische  Werkstätten  GmbH,  Munich,
Germany).
Experimental  protocol
Determination  of  the  seizure  threshold  dose  of  rocuronium
bromide  (Pilot  study): To  determine  the  seizure  threshold
dose  of  rocuronium  bromide,  a  total  of  12  rats  were  ran-
domized  into  2  groups.
Group  rocuronium  (n  =  6):  To  determine  the  seizure
threshold  dose,  a  vinyl-coated  polyethylene  adapter  was
attached  to  the  ICV  cannula  and  a  Hamilton  micro-syringe
was  attached  to  this  adapter  (Hamilton® 710SNR  100  L
Syringe  Hamilton  710  series  syringe,  NV,  USA).  Rocuro-
nium  bromide  (0.016  moL  ×  10  L−1,  total  0.08  moL)  was
injected  via  the  Hamilton  syringe  in  divided  doses  of  5  L.
Each  dose  was  administered  consecutively  over  60  s,  dur-
ing  which  time  the  effects  of  the  dose  on  the  rats  were
observed.  The  total  dose  required  to  induce  a  tonic-clonic
seizure  was  recorded.
Group  control  (n  =  6):  A  total  of  50  L of  Ringer’s  lactate
solution,  in  divided  doses  of  5  L,  was  administered  via  the
ICV  cannula,  as  explained  above.  The  rats  that  did  not  have
seizures  were  sacriﬁced  after  a  6  h  observation  period.
Dose-response  study  groups  (experimental  study): After
the  determination  of  the  seizure  threshold  dose  of  rocuro-
nium  bromide,  the  rats  were  randomized  into  4  groups  for
the  dose-response  study.
Group  1  (Group  C)  (n  =  6):  Ten  microliters  of  a  mixture  of
Ringer’s  lactate  solution  and  acetic  acid  with  a  pH  identical
to  that  of  the  rocuronium  solution  that  induced  seizures  was
administered  with  the  Hamilton  syringe  over  60  s.
Group  2  (Group  R  1/5)  (n  =  6):  Using  the  same  method  as
that  used  for  Group  C,  1/5  of  the  seizure  dose  of  rocuronium
0
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as  added  to  the  Ringer’s  lactate  solution  to  obtain  a  total
olution  volume  of  10  L  and  administered  to  the  rats.
Group  3  (Group  R  1/10)  (n  =  6):  Using  the  same  method
s  that  used  for  Group  C,  1/10  of  the  seizure  dose  of  rocuro-
ium  was  added  to  the  Ringer’s  lactate  solution  to  obtain  a
otal  solution  volume  of  10  L and  administered  to  the  rats.
Group  4  (Group  R  1/100)  (n  =  6):  Using  the  same  method
s  that  used  for  Group  C,  1/100  of  the  seizure  dose  of  rocuro-
ium  was  added  to  the  Ringer’s  lactate  solution  to  obtain  a
otal  solution  volume  of  10  L and  administered  to  the  rats.
Assessment  of  the  effects  of  intracerebroventricu-
ar  rocuronium  bromide:  A  ﬁve-point  scale  was  used  to
ssess  the  CNS  effects  of  rocuronium  bromide  administered
ntracerebroventricularly.8
0  =  no  observable  effects
1  =  decreased  locomotor  activity  and/or  piloerection
2  =  agitation  or  shivering
3 =  entire  body  tremors,  posturing,  or  splayed  limbs
4  =  tonic-clonic  convulsions  or  seizures
ermination  of  the  study
he  animals  that  had  seizures  were  immediately  sacriﬁced
ith  an  intraperitoneal  injection  of  120  mg/kg−1 sodium
hiopental.  The  animals  that  did  not  have  a  seizure  were
bserved  for  6  h  and  sacriﬁced  with  120  mg/kg−1 intraperi-
oneal  sodium  thiopental  at  the  end  of  the  study.
All  the  animals  were  injected  postmortem  with  50  L  of
ethylene  blue  via  the  permanent  cannula  into  the  cerebral
entricle,  and  the  brain  was  bisected  along  the  longitu-
inal  ﬁssure  to  examine  whether  the  dye  was  uniformly
istributed  within  the  ventricle.
tatistical  analysis
he  statistical  analyses  were  performed  using  the  SPSS
or  Windows  v.  11.0  statistical  package.  The  results
re  expressed  as  the  mean  ±  standard  deviation.  The
ruskal--Wallis  test,  followed  by  the  Mann--Whitney  U  and
isher’s  exact  tests,  was  used  for  the  between-group  com-
arisons.  The  within-group  comparisons  were  conducted
sing  Friedman  and  Wilcoxon  tests,  and  p  <  0.05  was  con-
idered  statistically  signiﬁcant.
esults
etermination  of  seizure  threshold  (pilot  study)
he  rats  in  the  control  group,  which  received  a  total  of  50  L
f  Ringer’s  lactate  solution  (pH  =  5.2)  in  the  lateral  cerebral
entricles,  did  not  exhibit  any  behavioral  alterations.
In  the  rocuronium  group,  the  seizure  threshold  for
CV  rocuronium  bromide  (pH  =  3.6)  was  found  to  be
.056  ±  0.009  moL.  The  volume  necessary  to  induce  a
eizure  was  found  to  be  35.0  ±  5.48  L.  The  seizure  thresh-
ld,  as  a  function  of  the  body  weight  of  rats,  was  calculated
s  0.286  moL/kg−1 (Table  1).
4  
Table  1  Rocuronium  bromide  doses  and  volumes.
Weight
(g)
Dose
(moL)
Dose
(moL/kg)
Volume
(L)
201  0.064  0.326  40
198 0.064  0.331  40
212 0.064  0.308  40
206 0.048  0.239  30
198 0.048  0.248  30
184 0.048  0.267  30
The seizure threshold, as a function of the body weight of rats,
was calculated as 0.286 moL/kg.
Table  2  CNS  effects  of  rocuronium  at  1/5  of  the  seizure
threshold  dose.
Weight  (g)  CNS  effect  Score
189  Seizure  4
266 Extremity  gets  a  posture  3
232 Extremity  gets  a  posture  3
238 Extremity  gets  a  posture  3
199 Extremity  gets  a  posture  3
184 Seizure  4
Table  3  CNS  effects  of  rocuronium  at  1/10  of  the  seizure
threshold  dose.
Weight  (g)  CNS  effect  Score
194  Shivering  2
180 Extremity  posture  2
182 Extremity  posture  2
217 Agitation  3
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189 Shivering  2
valuation  of  the  dose-response  results  study
experimental  study)
he  pH  values  of  the  Group  C,  Group  R  1/5,  Group  R  1/10,
nd  Group  R1/100  were  determined  to  be  3.6,  3.9,  4.1,  and
.8,  respectively.
In  this  study,  we  found  that  1/5  of  the  seizure  thresh-
ld  dose  typically  caused  splayed  limbs,  posturing,  and
ntire  body  tremors,  whereas  1/10  of  the  seizure  threshold
ose  caused  agitation  and  shivering  (Tables  2  and  3).  One-
undredth  of  the  seizure  threshold  dose  was  associated  with
ecreased  locomotor  activity  (Table  4).  The  effects  observed
Table  4  CNS  effects  of  rocuronium  at  1/100  of  the  seizure
threshold  dose.
Weight  (g)  CNS  effect  Score
218  Decreased  locomotor  activity  2
196 Decreased  locomotor  activity  1
192 Decreased  locomotor  activity  3
202 Decreased  locomotor  activity  1
186 Shivering  2
191 Decreased  locomotor  activity  1
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t  these  doses  gradually  improved  over  a 1-h  period  and
ere  then  maintained  as  reduced  locomotor  activity.  The
nimals  were  observed  for  a  total  of  6  h,  during  the  time
hen  feeding  and  motor  behaviors  became  comparable  to
hose  of  the  control  group.
iscussion
n  this  study,  we  found  that  rocuronium  administered  into
he  central  nervous  system  of  rats  through  the  cerebral
entricles  caused  seizures  when  the  rats  were  not  under
nesthesia  and  that  the  seizure  threshold  dose  of  rocuro-
ium  was  0.286  moL/kg−1. We  determined  during  the
ose-response  study  that  1/5  and  1/10  of  the  seizure
hreshold  dose  of  rocuronium  yielded  excitatory  responses,
hile  1/100  of  the  dose  resulted  in  decreased  locomotor
ctivity.
In  the  pilot  study,  behavioral  changes  were  not  observed
n  the  rats  when  we  administered  100  L  of  Ringer’s  lac-
ate  solution  at  a rate  of  5  L/min−1.  We  administered  a
aximum  of  40  L  while  determining  the  epileptic  seizure
hreshold  dose.  We  do  not  hypothesize  that  the  volume  of
he  drug  is  responsible  for  the  CNS  changes  observed  in  rats.
n  this  study,  we  determined  that  the  pH  of  the  drug  admin-
stered  via  the  ICV  cannula  was  not  a  contributing  factor  to
he  induction  of  seizures  because  only  reduced  locomotor
ctivity  was  observed  in  Group  1.
In  a similar  study,  Szenohradszky  and  colleagues  admin-
stered  atracurium,  pancuronium,  and  vecuronium  into  the
NS  and  observed  the  side  effects,  ﬁnding  the  epileptic
eizure  potencies  of  atracurium  >  pancuronium  >  vecuronium
0.12,  0.26,  and  0.46  moL/kg−1,  respectively).8 In  the
resent  study,  the  potency  of  rocuronium  necessary  to
ause  seizures  was  found  to  be  near  that  of  pancuro-
ium.
In  cases  in  which  neuromuscular  blocking  drugs  have  been
dministered  accidentally  into  the  CSF,1 the  diffusion  of
ocuronium  into  the  neuronal  tissue  from  cerebrospinal  ﬂuid
s  likely  a  function  of  molecular  weight,  lipid  solubility,  and
ime.9 Based  on  the  physical  properties  of  rocuronium,  it  is
ikely  to  remain  in  the  cerebrospinal  ﬂuid  after  injection,
ith  rapid  penetration  into  neuronal  tissues  being  unlikely.9
rugs  in  the  cerebrospinal  ﬂuid  can  be  redistributed  into  the
eripheral  circulation  by  transport  across  the  blood--brain
arrier.  An  ICV  infusion  may,  in  some  instances,  mimic  a
low  intravenous  infusion.10 We  did  not  observe  such  an  inci-
ence  at  any  stage  of  the  study,  which  may  have  occurred
ecause  the  dose  of  rocuronium  that  entered  the  systemic
irculation  was  not  sufﬁcient  to  reach  the  concentration
ecessary  to  reach  the  neuromuscular  junction  and  cause
uscle  relaxation.
ICV-administered  drugs  may  exert  receptor-mediated
ffects  at  or  near  the  brain-cerebrospinal  ﬂuid  interface.
ocuronium  is  a quaternary  ammonium  compound.  The
ositive  charge  of  this  molecule  mimics  that  of  the  qua-
ernary  nitrogen  atom  of  Acetylcholine  (Ach).  This  atom
s  the  major  contributor  to  the  effects  of  rocuronium  on
he  neuronal  nAchr.11 There  are  insufﬁcient  data  on  the
inetics  of  the  distribution  of  muscle  relaxants  in  the  CSF
hen  administered  into  the  cerebral  ventricles,8,12 and  it
s  not  known  in  which  part  of  the  brain  the  ACh  receptors
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1
1
1
1
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mediate  the  inhibitory  and  excitatory  effects  observed  with
rocuronium.
As  with  all  muscle  relaxants,  the  site  of  action  of  rocuro-
nium  is  the  postsynaptic  ACh  receptor  at  the  neuromuscular
junction.  In  an  experimental  study,  Jonsson  et  al.13 demon-
strated  that  rocuronium  inhibited  muscular  and  neuronal
nAchr.  Neuronal  nAchr  is  irreversibly  inhibited  by  rocuro-
nium  at  the  micro-molar  level  in  a  concentration-dependent
manner.  These  ﬁndings  suggest  that  rocuronium  exerts  only
inhibitory  effects  on  the  ACh  receptors  in  the  neuromuscular
junction,  while  it  exerts  inhibitory  and  excitatory  effects  on
the  nicotinic  ACh  receptors  in  the  CNS.
Fuchs-Buder  et  al.6 and  Tassonyi  et  al.14 reported  that
neuromuscular  blocking  agents  may  affect  the  CNS,  as
evidenced  by  the  induction  of  apnea.
Shao  et  al.15 demonstrated  that  the  cholinergic  nervous
system  is  important  in  the  regulation  of  respiratory  patterns,
and  inhibition  of  nAch  may  cause  central  depression  of  res-
piration.  In  our  study,  we  observed  no  sign  of  depression  of
respiration  or  apnea.
The  behavioral  changes  in  rats  manifested  as  decreased
locomotor  activity  after  1  h  and  recovery  of  normal  move-
ment  and  feeding  behavior  after  6  h  were  attributed  to  rapid
CSF  clearance,  which  is  2.83  L/min−1 in  rats.16 Because  the
CSF  volume  in  rats  is  500  L,  the  total  CSF  clearance  time  is
176  min.4,8 Meulemans  et  al.17 reported  that  45%  of  the  CSF
of  a  290  g  rat  was  cleared  in  1  h,  which  is  in  accordance  with
our  ﬁndings.
The  exact  mechanisms  of  action  of  muscle  relaxants  on
the  central  nervous  system  have  not  been  established.  This
study  showed  that  rocuronium  is  effective  on  the  CNS  and
has  dose-related  deleterious  effects.  Based  on  the  results
of  this  study,  it  is  not  possible  to  establish  a  relationship
between  the  effects  of  rocuronium  in  humans  and  rats.  The
amount  of  rocuronium  accumulation  in  the  cerebrospinal
ﬂuid  in  patients  receiving  long-term  rocuronium  infusion  is
unknown.
It  should  be  considered  that  CNS  effects  can  be  observed
if  rocuronium  is  infused  over  longer  periods  of  time  and  in
cases  in  which  the  blood--brain  barrier  is  compromised  or
rocuronium  is  administered  inadvertently  during  a  regional
block.Conﬂicts of interest
The  authors  declare  no  conﬂicts  of  interest.
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